Cencora, Inc. (NYSE:COR) Shares Sold by Bridgewater Associates LP

Bridgewater Associates LP lowered its position in shares of Cencora, Inc. (NYSE:COR) by 7.1% in the third quarter, HoldingsChannel.com reports. The firm owned 237,450 shares of the company’s stock after selling 18,016 shares during the quarter. Bridgewater Associates LP’s holdings in Cencora were worth $53,445,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of COR. New Millennium Group LLC acquired a new position in shares of Cencora during the 2nd quarter worth about $26,000. LRI Investments LLC acquired a new position in Cencora in the first quarter valued at approximately $31,000. MFA Wealth Advisors LLC purchased a new position in Cencora in the second quarter valued at approximately $30,000. Concord Wealth Partners acquired a new stake in Cencora during the third quarter worth approximately $30,000. Finally, SYSTM Wealth Solutions LLC purchased a new stake in shares of Cencora during the 2nd quarter worth approximately $36,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Trading Up 1.7 %

Shares of COR stock opened at $248.40 on Wednesday. Cencora, Inc. has a twelve month low of $195.83 and a twelve month high of $251.56. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84. The business’s 50 day moving average is $233.56 and its two-hundred day moving average is $232.01. The company has a market capitalization of $48.95 billion, a P/E ratio of 33.08, a price-to-earnings-growth ratio of 1.63 and a beta of 0.44.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, November 29th. Stockholders of record on Friday, November 15th will be issued a $0.55 dividend. This is an increase from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date is Friday, November 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.89%. Cencora’s payout ratio is presently 29.29%.

Analysts Set New Price Targets

A number of research firms recently commented on COR. JPMorgan Chase & Co. increased their target price on shares of Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research report on Wednesday, August 21st. UBS Group lifted their target price on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Leerink Partners decreased their target price on Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research report on Monday, October 7th. StockNews.com downgraded Cencora from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 20th. Finally, Robert W. Baird boosted their price objective on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $271.20.

Insiders Place Their Bets

In related news, Chairman Steven H. Collis sold 50,000 shares of Cencora stock in a transaction on Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the completion of the transaction, the chairman now directly owns 326,557 shares of the company’s stock, valued at approximately $79,670,111.29. The trade was a 13.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In the last 90 days, insiders have sold 93,018 shares of company stock worth $22,478,942. Company insiders own 15.80% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.